Identification of a duplicated V3 domain in NS5A associated with cirrhosis and hepatocellular carcinoma in HCV-1b patients by Le Guillou-Guillemette, H. et al.
Identification of a duplicated V3 domain in NS5A
associated with cirrhosis and hepatocellular carcinoma
in HCV-1b patients
H. Le Guillou-Guillemette, A. Ducancelle, S. Bertrais, C. Lemaire, A. Pivert,
P. Veillon, E. Bouthry, S. Alain, V. Thibault, F. Abravanel, et al.
To cite this version:
H. Le Guillou-Guillemette, A. Ducancelle, S. Bertrais, C. Lemaire, A. Pivert, et al.. Iden-
tification of a duplicated V3 domain in NS5A associated with cirrhosis and hepatocellular




Submitted on 25 Nov 2015
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.


















TITLE PAGE 2 
Title: Identification of a duplicated V3 domain in NS5A associated with cirrhosis and 3 
hepatocellular carcinoma in HCV-1b patients 4 
Authors: H Le Guillou-Guillemette 
a,b
, A Ducancelle 
a,b
, S Bertrais 
b
, C Lemaire 
c
, A Pivert 
a,b
 5 
, P Veillon 
a,b
, E Bouthry 
a,b 
, S Alain 
d
, V Thibault 
e
, F Abravanel 
f
, AR Rosenberg 
g
, C 6 
Henquell 
h
, E André-Garnier 
i
, O Petsaris 
j
, S Vallet 
j
, JB Bour 
k
, Y Baazia 
l
, P Trimoulet 
m
, P 7 
André 
n
, C Gaudy-Graffin 
o
, D Bettinger 
p
, S Larrat 
q
, A Signori-Schmuck 
q
, H Saoudin 
r
, B 8 
Pozzetto 
r
, G Lagathu 
s
, S Minjolle-Cha 
s
, F Stoll-Keller 
t
, JM Pawlotsky 
u
, J Izopet 
f
, C Payan 9 
j




 Laboratoire de Virologie, CHU Angers, France (heleguillou@chu-angers.fr; adpivert@chu-11 
angers.fr; sandrine.bertrais@univ-angers.fr; paveillon@chu-angers.fr; alducancelle@chu-12 
angers.fr; elise.bouthry@abc.aphp.fr; frlunel-fabiani@chu-angers.fr) 13 
b
HIFIH Laboratory, UPRES 3859, SFR 4208, LUNAM University, Angers, France 14 
c
IRHS, PRES LUNAM, SFR QUASAV, Angers, France (christophe.lemaire@univ-angers.fr) 15 
d
 Laboratoire de Virologie, CHU  Limoges, France (sophie.alain@unilim.fr) 16 
e
Laboratoire de Virologie, CHU Pitié-Salpêtrière, Paris, France (vincent.thibault@psl.aphp.fr) 17 
f
Laboratoire de Virologie, CNR VHE, Inserm U1043, CHU Purpan, Toulouse, France 18 
(abravanel.f@chu-toulouse.fr; izopet.j@chu-toulouse.fr) 19 
g
AP-HP, GHU Cochin, Laboratoire de Virologie, Université Paris Descartes, EA 4474 20 
"Hepatitis C Virology", Paris, France (arielle.rosenberg@parisdescartes.fr) 21 
h
Laboratoire de Virologie, CHU Clermont-Ferrand, France (chenquell@chu-22 
clermontferrand.fr) 23 

















 Laboratoire de Virologie, CHU Hôtel Dieu, Nantes, France (elisabeth.andre@chu-nantes.fr) 24 
j
Département de Bactériologie-Virologie-Hygiène Hospitalière et Parasitologie-Mycologie, 25 
CHRU, LUBEM, EA3882, Brest, France (odilepetsaris@yahoo.fr; sophie.vallet@chu-26 
brest.fr; christopher.payan@chu-brest.fr) 27 
k
 Laboratoire de Virologie, CHU, Dijon, France (Jean-Baptiste.Bour@u-bourgogne.fr) 28 
l 
Laboratoire de Virologie, CHU Avicenne, Bobigny, France (yazid.baazia@sls.aphp.fr) 29 
m
Laboratoire de Virologie, Hôpital Pellegrin Tripode, CHU Bordeaux, France 30 
(pascale.trimoulet@chu-bordeaux.fr) 31 
n
Laboratoire de Virologie, Centre de Biologie Nord, Hôpital de la Croix Rousse, Lyon, France 32 
(patrice.andre@chu-lyon.fr) 33 
o
Université François Rabelais, Inserm U966, CHU Tours, France (gaudy_c@med.univ-34 
tours.fr) 35 
p
 Laboratoire de Virologie, CHU Besançon, France (dbettinger@chu-besançon.fr) 36 
q
Laboratoire de Virologie, UMI 3265 UJF-EMBL-CNRS, CHU, Unit of Virus Host Cell 37 
Interactions, Grenoble, France (SLarra @chu-grenoble.fr; asignorischmuck@chu-grenoble.fr) 38 
r
Laboratoire de Bactériologie-Virologie, CHU Saint-Etienne, France (henia.saoudin@chu-st-39 
etienne.fr; Bruno.Pozzetto@chu-st-etienne.fr) 40 
s
Laboratoire de Virologie, CHU Rennes, France (Gisele.LAGATHU@chu-rennes.fr; 41 
sophie.minjolle@chu-rennes.fr) 42 
t
Institut de Virologie, CHU Strasbourg, Inserm U748, Strasbourg, France 43 
(francoise.stoll@unistra.fr) 44 
u
Laboratoire de Virologie-Bactériologie, CHU Henri-Mondor, Créteil, France (jean-45 
michel.pawlotsky@hmn.aphp.fr) 46 
 47 
















Corresponding author: Dr Hélène Le Guillou-Guillemette, Laboratoire de Virologie, 48 
Département des agents infectieux, IBS, CHU Angers, 4 rue Larrey 49933 Angers cedex9, 49 
France. Phone: 33-241354709. Fax: 33-241354164. E-mail: heleguillou@chu-angers.fr 50 
 51 





Background. The NS5A protein of the hepatitis C virus has been shown to be involved in the 57 
development of hepatocellular carcinoma.  58 
Objectives. In a French multicenter study, we investigated the clinical and epidemiological 59 
features of a new HCV genotype 1b strain bearing a wide insertion into the V3 domain.  60 
Study Design. We studied NS5A gene sequences in 821 French patients infected with 61 
genotype 1b HCV.  62 
Results. We identified an uncharacterized V3 insertion without ORF disruption in 3.05% of 63 
the HCV sequences. The insertion comprised 31 amino-acids for the majority of patients; 3 64 
patients had 27 amino-acids insertions and 1 had a 12 amino-acids insertion. Sequence 65 
identity between the 31 amino-acids insertions and the V3 domain ranged from 48 to 96% 66 
with E-values above 4e
-5
, thus illustrating sequence homology and a partial gene duplication 67 
event that to our knowledge has never been reported in HCV. Moreover we showed the 68 
















presence of the duplication at the time of infection and its persistence at least during 12 years 69 
in the entire quasispecies. No association was found with extrahepatic diseases. Conversely, 70 
patients with cirrhosis were two times more likely to have HCV with this genetic 71 
characteristic (p=0.04). Moreover, its prevalence increased with liver disease severity (from 72 
3.0% in patients without cirrhosis to 9.4% in patients with both cirrhosis and HCC, p for 73 
trend=0.045).  74 
Conclusions. We identified a duplicated V3 domain in the HCV-1b NS5A protein for the first 75 
time. The duplication may be associated with unfavorable evolution of liver disease including 76 
a possible involvement in liver carcinogenesis. 77 
Key words: cirrhosis, hepatitis C virus, hepatocellular carcinoma, NS5A, V3 domain 78 
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Infection by hepatitis C virus (HCV) becomes persistent in around 80% of cases and in turn a 81 
major cause of liver disease for the approximately 184 million HCV patients worldwide. 82 
Chronically infected patients are at risk of developing liver cirrhosis and hepatocellular 83 
carcinoma (HCC) [1]. 84 
HCV is a single-strand RNA virus belonging to the Flaviviridae family. Its genome encodes a 85 
polyprotein of about 3000 amino-acids that is then cleaved into structural and non-structural 86 
proteins such as NS5A, a pleiotropic phosphoprotein. Thus, studies strongly suggest that 87 
NS5A plays a role in resistance to interferon (IFN)-based therapy [2], in the establishment of 88 
chronic hepatitis and in liver carcinogenesis [3]. NS5A is now a target for antivirals [4]. 89 
HCV is notable for its considerable genetic diversity [5]. Indels are one feature of the genetic 90 
variability characterizing RNA virus evolution, but the physiopathological consequences of 91 
these changes in HCV have not been well explored. Thus, Gerotto et al. showed that a 1-92 
amino-acid insertion or deletion in HVR1 was significantly associated with mixed 93 
cryoglobulinemia type 2 [6]. Other authors have correlated indels in the NS5A domain with 94 
genotype specific signatures and suggested a putative role in the resistance to antiviral therapy 95 
or host immune response evasion [7]. Conversely, gene duplications have been described as a 96 
major evolutionary tool for DNA viruses [8]. This allows for the acquisition of new biological 97 
functions or the modification of virulence. However, biological constraints make gene 98 
duplication extremely rare in RNA viruses [9]. 99 
 100 
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In previous studies [10, 11] in HCV-1b-infected patients, we discovered a NS5A 103 
polymorphism that may consist in V3 domain duplication, a variable region located in the 104 
NS5A domain III. One of those patients had extrahepatic disease. To better understand this 105 
unknown but intriguing HCV polymorphism at NS5A gene, we performed an observational 106 
cross-sectional multicenter study. Thus, using both clinical and phylogenetic data, we 107 
questioned i) the impact of the duplication of V3 domain on the probability of HCC, ii) the 108 
prevalence of V3-duplication in patients and iii) the persistence of V3-duplicated strains 109 
during the infection process.  110 
111 
















Study design 112 
Study Patients 113 
All consecutive patients newly diagnosed with chronic HCV-1b infection and without HIV 114 
co-infection were selected at the routine genotyping step in 19 French academic laboratory of 115 
virology between 2006 and 2009. We initially enrolled 938 patients; 117 patients were 116 
subsequently excluded due to failed NS5A amplification (HCV viral load was weak or 117 
undetectable). Excluded patients did not significantly differ regarding disease duration, date 118 
of diagnosis and alcohol abuse (data not shown). Consequently, the present cross-sectional 119 
study was conducted in 821 patients. 120 
 121 
Demographic and clinical data 122 
Date of blood sample collection and biological parameters including HCV genotype, viral 123 
load and biochemical measures were obtained from the participating laboratories. 124 
Demographic (age, gender) and clinical (fibrosis evaluation and presence of cirrhosis, 125 
presence of HCC, cryoglobulinemia, lymphoma or co-infection, presumed date of infection 126 
and route of transmission if available) data at the time of inclusion were retrospectively 127 
collected from medical records. Thus, we were able to determine fibrosis stages or the 128 
presence of cirrhosis in 542 patients. 129 
NS5A amplification and nucleotide sequencing 130 
HCV RNA was extracted from 200 µL of each serum sample using the EasyMag automated 131 
extraction system (BioMérieux, Craponne, France). As previously described [12], the full 132 
length NS5A gene was amplified by nested RT-PCR. Each PCR product that showed a larger 133 
















fragment than expected was sequenced in two directions using the Big Dye Terminator v3.1 134 
Cycle Sequencing Kit (Applied Biosystems) on the automated ABI3130xl [12]. We also 135 
always used the Superscript III reverse transcriptase/platinum Taq polymerase (Invitrogen) to 136 
rule out PCR artifacts. 137 
PCR products from consecutive serums with V3-insertion were also submitted to a clonal 138 
quasispecies analysis using the protocol that we previously described [10]. A mean of 30 139 
clones per sample was analyzed. The amino-acids residues were numbered according to the 140 
sequence of the HCV-1b HCV-J prototype (Genbank Accession number: D90208). 141 
Sequence analysis of the NS5A gene 142 
When both were present, the amino-acids sequences of the inserted domain and the V3 143 
domain were compared pairwise using BLASTP [13]. Sequences were considered 144 
homologous when the expected (E)-value was above 10
-5
. This cut-off has already been used 145 
to assess duplication events in RNA viruses and was considered relatively stringent [14]. 146 
The sequence data were deposited in the DDBJ/EMBL/GenBank nucleotide sequence 147 
databases: accession numbers KF420489-KF420513. 148 
Evolution of the V3-duplicated strains in one patient 149 
In order to test for the functionality of strains carrying the duplication of V3 domain during 150 
infection, we performed the detection of the V3-insertion in 5 consecutive serums covering a 151 
twelve years follow-up of one patient. We had the serum before the contamination, at the time 152 
of the transmission in 1988 (by a kidney graft) and during the HCV chronic disease (1996, 153 
1998 and 2000). In order to trace the evolutionary relationships of strains during time, we 154 
used the phylogenetic method implemented in the software BEAST v.1.8 [15]. Prior to any 155 
















inference the more likely substitution model was tested using jModelTest 2 [45]. The best 156 
model was found to be the HKY substitution model [46] with gamma heterogeneity and a 157 
proportion of invariant sites. This substitution model was used when useful in analyses using 158 
BEAST. Coalescent simulations assuming a strict clock model of substitution rate were run 159 
under the Bayesian Skyline model [16] that assumes demographic variations. Three 160 
independent runs were performed to assess convergence of the Monte Carlo Markov Chain 161 
process. 162 
Statistical analyses 163 
Statistical analyses were performed using SAS version 9.3 (SAS Institute, Inc., USA). The 164 
distribution of categorical variables was expressed as frequencies and percentages. 165 
Quantitative variables were described in mean values +/- standard deviation (SD) and median. 166 
Differences between patient groups were analyzed using the Fisher’s exact test for nominal 167 
variables and the non-parametric Mann-Whitney-Wilcoxon test for continuous variables, 168 
unless otherwise indicated. 169 
To assess the clinical relevance of the NS5A V3 insertion, we firstly compared the proportion 170 
of patients having this genetic characteristic as a function of several diseases. For this, 95% 171 
confidence intervals (CI) were calculated by the exact method assuming binomial distribution. 172 
We additionally performed an exact Cochran-Armitage trend test to assess whether the 173 
proportion of patients having the NS5A V3 insertion increased with liver disease severity (no 174 
cirrhosis, cirrhosis without HCC, cirrhosis with HCC). We also fitted multivariate ordinal 175 
logistic regression model to assess the relationship of the NS5A insertion with the 3 176 
categories of liver disease severity. The proportional odds assumption underlying ordinal 177 
logistic regression was checked and was not rejected (p>0.15).Other factors which were 178 
















significantly related to liver disease severity in univariate analysis, were also tested in the 179 
multivariate logistic regression model. 180 
181 

















Identification of a duplicated V3 domain in the NS5A gene 183 
Twenty-five of the 821 test subjects were infected by an HCV-1b strain bearing a NS5A gene 184 
longer than expected. Direct NS5A sequencing of these samples revealed V3 domain 185 
duplication. Insertion lengths were 31 amino-acids for 21 patients, 27 amino-acids for three, 186 
and 12 amino-acids for one. The two V3 domains appeared in tandem without ORF disruption 187 
(Figure 2). The duplicated domains presented strong sequence similarities with a level of 188 





The prevalence of this novel duplication in our cohort was 3.05% (95% CI: 1.98-4.46) 190 
without particular geographical localization. 191 
Longitudinal analysis of the presence of the V3-insertion 192 
A total of 112 different sequences of the NS5A gene were obtained across the four sampling 193 
times. All NS5A haplotypes carried the V3-insertion. The V3-insertion was then present since 194 
the infection and persisted for the 12 years. We did not observe any co-occurrence of 195 
haplotype of both haplotyp  with and without insertion within the same serum. The 196 
evolutionary relationship between haplotypes represented in Figure 2A showed the evolution 197 
of NS5A within the patient during the 12 years. Haplotype occurring at time t+1 derived from 198 
a small number of haplotypes present a time t. The bayesian skyline plot in Figure 2B 199 
indicates a quasi-constant population size during the 12 years. In addition, we also analysed 200 
consecutive serum available for two others patients covering a period of 5 and 6 years 201 
respectively. The V3-insertion was present in all the samples by direct and clonal sequencing. 202 
















Comparison between patients infected by the mutant HCV strain and those infected by wild-203 
type HCV 204 
Patient characteristics according to V3 status are shown in Table 1. The only difference 205 
between the two groups was that patients infected by an HCV virus bearing a V3 duplicated 206 
domain were older (p=0.035). No differences were found in terms of sex ratio, disease 207 
duration or HCV viral load. 208 
In the subsample of patients for whom infection information was available, time since 209 
infection was highly related to age (Spearman rank correlation coefficient r=0.47, p<0.0001) 210 
but did not significantly differ according to V3 duplication status (p=0.91). 211 
Clinical relevance of the V3 duplication 212 
To assess possible relationships between the V3 duplication and extrahepatic disease, we 213 
classified patients according to the presence of cryoglobulinemia or lymphoma. No significant 214 
difference in the prevalence of V3 duplication was observed between patients having 215 
cryoglobulinemia or lymphoma as compared to those free of these extrahepatic diseases 216 
(Figure 3A). 217 
In contrast, a significant relationship was found between V3 duplication and liver disease. The 218 
proportion of patients having the mutant strain was two times higher in patients with 219 
hepatocellular carcinoma compared to those without. We also found a significant association 220 
between the presence of the V3 duplication and cirrhosis (Figure 3B). Furthermore, the 221 
prevalence of the mutant strain increased with liver disease severity (p for trend=0.0449) 222 
(Table 2). Results from ordinal logistic regression analysis confirmed that there was a 223 
borderline significant relationship between V3 duplication and liver disease severity: the 224 
















unadjusted odds of having cirrhosis without or with HCC versus being non-cirrhotic was 2.4 225 
times greater in patients with V3 duplication (OR [95% CI]: 2.41 [1.00-5.81], p=0.0502). Age 226 
and sex were also associated with liver disease severity (p=<0.0001 and p=0.016 227 
respectively), no significant relationship was found with alcohol consumption (p=0.60) and 228 
HCV viral load (p=0.35). After adjustment for age and sex, the odds-ratio remained higher 229 
than 2.0, although it was non-significant (OR [95% CI]: 2.06 [0.84-5.02], p=0.1123). Due to 230 
the proportional odds assumption of the ordinal logistic regression model, the presence of V3 231 
duplication was associated with the same two-fold increase in odds for having HCC versus 232 
the combined category “cirrhotic but no HCC” or “non-cirrhotic”, after controlling for age 233 
and sex. 234 
235 

















In our multicenter study, we found 25 cases with a high sequence identity between both V3 237 
domains, illustrating partial gene duplication in NS5A. In our test population, the prevalence 238 
of the strain was 3.05% (95% CI: 1.98-4.46). Authors recently reported that gene duplication 239 
is infrequent in RNA viruses: they identified only nine cases of gene duplication among 1198 240 
RNA virus species analyzed using a BLAST approach [14]. Specifically in HCV, insertion or 241 
deletion is quite rare. A large quasispecies study identified only infrequent, very small (from 1 242 
to 4 amino-acids) insertions in the E1-E2 or NS5A regions of HCV-1. This work 243 
demonstrated that insertions were detected in all the specimens comprising sequential samples 244 
but not always in all the clones [17]. Here we detect an insertion that was not only large but 245 
also a tandemly repeated domain. Moreover, an analysis performed at the quasispecies level 246 
showed that the V3 duplication was present in 100% of the clones of the 25 mutant HCVs 247 
(n=870 clones, with a mean of 30 clones per sample). We also identified the V3 duplication 248 
following HCV infection and its persistence in three patients. This temporal analysis 249 
permitted to conclude that the clones with V3-insertions had the ability to infect patients and 250 
persist during several years like clones without insertion. Others studies have described small 251 
indels in the 5’UTR [18] or in the E1-E2 region, especially in the HVR1 subdomain [19]. In 252 
our work, the insertion contained 31 amino-acids for almost all of the mutant HCVs (21/25). 253 
Furthermore, Moradpour et al. demonstrated that domain III of NS5A tolerates wide 254 
heterologous insertion [20]. Our findings demonstrate that insertions are also naturally 255 
tolerated as suggested in vitro. In contrast, past reports of genomic HCV polymorphisms have 256 
mainly described recombinant strains; none described duplicated domains [21]. Gene 257 
duplication in RNA viruses is possible, but it is a contradictory evolutionary pathway. 258 
Duplication leads to increased genome size, which may lead to new evolutionary 259 
















opportunities, or conversely the enhancement of defects in production or replication [22]. The 260 
few cases of partial gene duplication reported in RNA viruses were located in untranslated 261 
regions of Flaviviridae [23, 24]. Thus, a high mutation rate offers a better evolutionary path 262 
for RNA viruses. Therefore, a prevalence of 3.05% for our mutated strain exhibiting 263 
duplication in the ORF should be considered as high. 264 
HCV infection severity has been linked to host parameters and virological characteristics. A 265 
number of reports have associated amino-acids variations in NS5A with issues in antiviral 266 
therapy [2, 10, 27] or the evolution of liver disease toward cancer [28, 29]. Recently, 267 
particular mutations in NS3 and NS5A were also showed to be more closely associated with 268 
the development of HCC [30]. Our results suggest that the identified polymorphism in NS5A 269 
may also be associated with a pejorative progression of liver disease. We observed that this 270 
V3 domain duplication was much more prevalent in patients with cirrhosis and HCC. 271 
Moreover, this prevalence increased with liver disease severity, and the relationship with liver 272 
complications remained strong after adjustment for sex and age, although non-significant. 273 
Clinical data for liver fibrosis were available for 551 patients with a cohort of 119 cirrhosis 274 
patients. These data were in accordance with the level of severe disease expected in the 275 
physiopathological history of HCV disease and sufficient to perform robust statistical 276 
analyses. We were unable to identify other factors that may potentially influence liver disease 277 
severity. In the present study, alcohol consumption and viral load level were not related to 278 
liver disease severity. Unfortunately, other well-established confounder factors were not 279 
available or only in a subsample of subjects. Date and route of transmission were not 280 
frequently recorded, as mostly observed in prospective studies [31]. Time since infection may 281 
be one of the potential confounding factors of the observed relationships with liver 282 
complications. However this factor was indirectly controlled by age adjustment in our study. 283 
















Indeed, we found a high correlation between time since infection and age among patients for 284 
whom this information was available. Moreover, in this subsample, time since infection lost 285 
its significant relation to liver complications after age adjustment (data not shown).  286 
Although we feel that the prevalence of the duplication in NS5A should be considered as 287 
elevated in the setting of RNA viruses and especially in that of HCV, the small number of 288 
patients with V3 insertions in our study population may lead to a lack of statistical power. 289 
This may explain the borderline or non-significant p-values and the wide confidence intervals, 290 
despite the strong observed differences. For these same reasons, the non-significant 291 
relationship with extrahepatic disease (cryoglobulinemia and lymphoma) should be 292 
interpreted cautiously. This kind of correlation was previously identified with single 293 
nucleotide insertions located in the HVR1-envelope [6]. Contrary to E1-E2, NS5A does not 294 
appear to be genuinely involved in immune system stimulation or clonal selection of 295 
lymphocytes. The V3 domain, located within NS5A domain III, has been shown to be 296 
dispensable for HCV replication in vitro [32], and our results suggest that its duplication does 297 
not influence viral load in vivo. Indeed, we observed no differences in viral loads as a function 298 
of V3 status. Here, we identified in a clinical study a wide duplication event in the NS5A 299 
protein of a HCV-1b strain that can be transmitted and persists, and may be associated with a 300 
higher risk of liver complications. The results of this cross-sectional study should be 301 
confirmed in a larger cohort. 302 
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FIGURE CAPTIONS 419 
 420 
Figure 1. Alignments of the 25 sequences showing a V3-NS5A duplicated domain with 421 
respect to the HCV-J 1b reference sequence. The first V3 domain is located between 422 
positions 2353 and 2383 (light grey column), the second is tandemly located thereafter out to 423 
position 2414 (dark grey column). Dots (.) represent identical residues; dashes (-) indicate 424 
shorter insertions in the last four aligned sequences; X denotes a mixture. 425 
 426 
Figure 2. Phylodynamics at gene NS5A for 112 strains of a patient during its infection 427 
since the year of the transmission (1988) until the last date of the clinical follow-up 428 
(2000). (A) Coalescent tree inferred using the Bayesian Skyline Model using BEASTv1.8. 429 
Colors correspond to sampling times of quasispecies (1988: yellow; 1996: orange; 1998: red 430 
and 2000: pink). (B) Demographic dynamics using the Bayesian Skyline Plot. Distribution of 431 
effective population sizes are plotted against time. Black line corresponds to the median of 432 
distribution and 95% of the highest posterior density is given in blue.  433 
 434 
Figure 3. Comparisons of the proportion of patients having the V3-duplicated HCV 435 
strain according to clinical status for two extrahepatic diseases cryoglobulinemia and 436 
lymphoma (A) and to the presence of HCC or cirrhosis (B). Error bars represent 95% 437 
confidence intervals. 438 
 439 
















Table 1. Characteristics of included patients according to HCV-1b NS5A V3 status 440 
    
 Total Presence of V3 duplication  
 n=821 No (n=796) Yes (n=25)  
 n (%) or mean (sd) 
/ median 
n (%) or mean (sd) / 
median 
n (%) or mean (sd) / 
median 
p 
Male (%) 50.3 50.3 48 0.84 
(a)
 
Age (years) 54.8 (14.6) / 54.7 54.6 (14.6) / 54.3 61.0 (14.2) / 59.7 0.035
(b)
 
Viral load (log 
UI/mL) 






n=191 n=176 n=15  





n=279 n=265 n=14  









 Fisher’s exact test; 
(b) 
Non-parametric Mann–Whitney–Wilcoxon test 441 
 442 
 443 
Table 2. Patient characteristics and observed prevalence of V3 duplication according to 444 
combined status for cirrhosis and hepatocellular carcinoma.  445 
     
 No cirrhosis 
Cirrhosis without 
HCC  
Cirrhosis with HCC  
















 n=432 n=87 n=32  
Variable 
% or mean (sd) / 
median 
% or mean (sd) / 
median 
% or mean (sd) / 
median 
p for linear 
trend 
Male (%) 44.1 51.8 68.7 0.0056 
(a)
 
Age (years) 54.1 (14.1) / 53.9 59.9 (12.2) / 62.0 65.2 (9.7) / 66.6 <0.0001 
(b)
 
Viral load (log 
IU/ml) 




(%), 95% CI 




  Cochran-Armitage test for trend; 
(b)
 General linear model including a linear contrast to test trend  446 
 447 
 448 
 449 
 450 
 451 
